Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Semaglutide in Early Alzheimer's Disease (EVOKE)
NCT04777396Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2021
- Primary completion
- Sep 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 37
01
Overview
A Phase 3 trial of semaglutide in Alzheimer's disease (AD), sponsored by Novo Nordisk. Started May 2021; status: completed.
02
Drugs
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04777396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04777396.